Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …
Sharemaestro market context Price below Trend Line 52 weeks +34.1% · Next-week setup positive 55.1%Bain Capital Life Sciences Opportunities III, LP has reported a 4.75% ownership stake in Kyverna Therapeutics, Inc. (KYTX) through a Schedule 13G/A SEC filing. The fund holds 2,885,000 shares of common stock, representing a passive investment based on the company's 60,795,212 outstanding shares as …
Fate Therapeutics (NASDAQ: FATE) announced second-quarter EPS of $-0.250, surpassing analyst estimates by $0.02, and reported revenue of $2.08 million, exceeding the consensus of $1.29 million. The company's stock has seen significant growth, rising 43.590% in the last three months and 131.190% over the …
Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …
Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …
Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …
Renaissance Technologies LLC significantly increased its stake in Q32 Bio Inc. by acquiring an additional 107,315 shares in the first quarter, bringing its total to 206,915 shares valued at $1.33 million. This comes as Q32 Bio reported better-than-expected quarterly earnings and several other institutional …
Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment …
Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …
Balyasny Asset Management and its affiliated entities have reported a 7.14% beneficial ownership stake in Contineum Therapeutics (CTNM) Class A common stock through a Schedule 13G/A filing. This equates to 2,335,550 shares, with sole voting and dispositive power, based on 32,723,877 shares outstanding as …
Valneva SE reported second-quarter earnings per share of $-0.39, missing analyst estimates by $0.18. The company's revenue for the quarter was $40.29 million, falling short of the consensus estimate of $44.17 million. Valneva SE's stock price has declined by -0.53% in the last 3 …
Innate Pharma has priced a €30 million share offering to fund the clinical development of its lead cancer drug candidate, IPH4502, and its preclinical antibody-drug conjugate portfolio. The French biotech issued 17,647,059 new ordinary shares at €1.70 each, expecting net proceeds of €27.6 million. …
Handelsbanken Fonder AB significantly increased its stake in Axsome Therapeutics, Inc. by 216.4% in the second quarter, now holding 42,400 shares valued at $10.38 million. This comes despite Axsome Therapeutics missing analyst expectations for both earnings and revenue in its latest quarterly report. The …
GH Research PLC (NASDAQ:GHRS) has received an average rating of "Moderate Buy" from analysts, with ten out of twelve recommending a buy and an average 12-month price target of $45.00 against a current price of $28.19. Despite beating quarterly earnings estimates, analysts foresee continued …
Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (IMMX) following a significant drop in its stock price. The investigation stems from the company's termination of its Chief Medical Officer, Richard Graydon, who was later identified by media outlets as Ronald …
Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …
Balyasny Asset Management and its affiliated entities have reported a 4.84% beneficial ownership stake in Rezolute, Inc. (RZLT) common stock through a Schedule 13G/A filing. This ownership amounts to 4,662,039 shares held via Atlas Diversified Master Fund, Ltd., representing 4.84% of Rezolute's outstanding shares …
Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to …
Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …
Balyasny Asset Management L.P. and its affiliated entities have disclosed a 7.33% beneficial ownership stake in Cyclerion Therapeutics, Inc. (CYCN). The group holds 317,511 shares of common stock through Atlas Diversified Master Fund, Ltd., exercising sole voting and dispositive power over these shares. This …
Balyasny Asset Management and its affiliated entities have disclosed a beneficial ownership of 7,844,311 shares of Lexeo Therapeutics, Inc. (LXEO) common stock, representing 9.99% of the outstanding shares. This stake includes shares directly held by Atlas Diversified Master Fund and Atlas Private Holdings, with …
Zacks Research has upgraded Inovio Pharmaceuticals (NASDAQ:INO) to a "strong-buy" rating. This upgrade comes as the company reported a quarterly loss of $0.07 per share, beating analyst expectations, and anticipates an FDA decision for its key product INO-3107 by October 30, 2026. The company …
Balyasny Asset Management and its related entities have disclosed a beneficial ownership of approximately 4.99% in Camp4 Therapeutics Corp. (CAMP). This stake, totaling 2,591,097 shares, includes common stock and shares issuable upon warrant exercise, which are subject to a 4.99% Beneficial Ownership Limitation to …
Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. …
Analysts have raised their fair value estimate for Fennec Pharmaceuticals (FENC) from US$15.33 to US$17.67 per share, attributing this increase to stronger-than-expected PEDMARK revenue, its expanded use across various tumor types, and improved operating leverage. Several firms, including B. Riley, Wedbush, and H.C. Wainwright, …
Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report …
Balyasny Asset Management L.P. and its affiliated entities have reported a 6.03% beneficial ownership stake in Crescent Biopharma, Inc., totaling 1,662,917 shares of Class A common stock. This ownership is primarily held through Atlas Private Holdings (Cayman) Ltd. and Atlas Diversified Master Fund, Ltd. …
For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …
Search by ticker symbol or company name and select a result to open its chart.